WG
MTNB icon

Winton Group’s Matinas BioPharma MTNB Stock Holding History

Winton Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-634
Closed -$41K – 1266
2021
Q3 		$41K Sell
634
-402
-39% -$17.3K ﹤0.01% 1308
2021
Q2 		$40K Sell
1,036
-731
-41% -$31.4K ﹤0.01% 1403
2021
Q1 		$93K Sell
1,767
-146
-8% -$9.79K 0.01% 1338
2020
Q4 		$130K Sell
1,913
-2,838
-60% -$131K 0.01% 1241
2020
Q3 		$182K Buy
4,751
+2,742
+136% +$109K 0.01% 1358
2020
Q2 		$78K Sell
2,009
-157
-7% -$6.02K ﹤0.01% 1407
2020
Q1 		$65K Sell
2,166
-1,140
-34% -$68.8K ﹤0.01% 1350
2019
Q4 		$375K Sell
3,306
-168
-5% -$9.73K 0.01% 1320
2019
Q3 		$110K Buy
+3,474
New +$126K ﹤0.01% 1455

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Winton Group's MTNB Position: Q4 2021 in Review

Winton Group sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 634 shares — an estimated $41K sold.

Winton Group first reported a position in MTNB in Q3 2019 and held it in 9 quarters. The position peaked at $375K in Q4 2019. 66 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

  • Winton Group reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 634 Matinas BioPharma shares in Q4 2021, an estimated $41K.
  • Winton Group first reported a position in Matinas BioPharma in Q3 2019 and held it in 9 quarters.
  • Winton Group's Matinas BioPharma position peaked at $375K in Q4 2019.
  • 66 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.